U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07005284) titled 'A Study of LY3981314 in Healthy Participants' on June 03.
Brief Summary: The main purpose of this study is to investigate the safety of LY3981314 when administered subcutaneously (SC) (under the skin), and how it's processed in the body.
The study will last approximately 25 weeks, excluding a screening period with an optional extension to approximately 49 weeks for qualifying participants.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Healthy
Intervention:
DRUG: LY3981314
Administered SC
DRUG: Placebo
Administered SC
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Eli Lilly and Company
Disclaimer: Cu...